Continuum Advisory LLC Acquires 201 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Continuum Advisory LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,739 shares of the medical research company’s stock after buying an additional 201 shares during the quarter. Continuum Advisory LLC’s holdings in IQVIA were worth $412,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Canada Pension Plan Investment Board lifted its position in shares of IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after buying an additional 211,653 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after purchasing an additional 86,870 shares during the last quarter. FMR LLC boosted its position in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the period. Impax Asset Management Group plc raised its position in shares of IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after purchasing an additional 157,809 shares during the period. Finally, Legal & General Group Plc lifted its stake in shares of IQVIA by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock valued at $320,170,000 after buying an additional 11,715 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE:IQV opened at $203.31 on Wednesday. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The business has a 50 day moving average of $214.57 and a 200 day moving average of $224.96. The company has a market capitalization of $36.90 billion, a price-to-earnings ratio of 26.68, a PEG ratio of 2.08 and a beta of 1.49.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Wednesday, December 4th. The Goldman Sachs Group decreased their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Morgan Stanley cut their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Evercore ISI lowered their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.